Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H21FN3O4.Na |
| Molecular Weight | 517.4829 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)[C@H](CC1=CC=C(OCC2=CC=C3C=CC(F)=CC3=N2)C=C1)NC(=O)C4=CC=C5C=CC=CC5=N4
InChI
InChIKey=KGZGMOFDZSCICN-YCBFMBTMSA-M
InChI=1S/C29H22FN3O4.Na/c30-21-10-7-20-8-11-22(31-26(20)16-21)17-37-23-12-5-18(6-13-23)15-27(29(35)36)33-28(34)25-14-9-19-3-1-2-4-24(19)32-25;/h1-14,16,27H,15,17H2,(H,33,34)(H,35,36);/q;+1/p-1/t27-;/m0./s1
| Molecular Formula | C29H21FN3O4 |
| Molecular Weight | 494.4931 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 10:11:12 GMT 2025
by
admin
on
Wed Apr 02 10:11:12 GMT 2025
|
| Record UNII |
5DC7F7S5N7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL3545273
Created by
admin on Wed Apr 02 10:11:12 GMT 2025 , Edited by admin on Wed Apr 02 10:11:12 GMT 2025
|
PRIMARY | |||
|
71474171
Created by
admin on Wed Apr 02 10:11:12 GMT 2025 , Edited by admin on Wed Apr 02 10:11:12 GMT 2025
|
PRIMARY | |||
|
1448619-70-2
Created by
admin on Wed Apr 02 10:11:12 GMT 2025 , Edited by admin on Wed Apr 02 10:11:12 GMT 2025
|
PRIMARY | |||
|
5DC7F7S5N7
Created by
admin on Wed Apr 02 10:11:12 GMT 2025 , Edited by admin on Wed Apr 02 10:11:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Intravenous (i.v.) administration of the agent both antagonized (ED50, 9.9+/-1.9 microg/kg) and reverted LTD4 -induced bronchoconstriction of anesthetized guinea pigs. CR3465 reduced inflammatory infiltrates in the bronchoalveolar lavage fluid after antigen challenge of sensitized animals, and proved also active in inhibiting phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) activities exhibited by human platelets and neutrophils (IC50, 2.01+/-0.07 and 4.7+/-0.5 microM). In line with properties shown by phosphodiesterase inhibitors, CR3465 reduced the contractile response of guinea pig airways to histamine and decreased N-formyl-Met-Leu-Phe (fMLP)-induced degranulation of human neutrophils (IC50, 13.8 microM).Pharmacokinetic data in the rat demonstrated approximately 100% bioavailability of the agent.
|